MedDataX Logo

Skeletal Muscle Index and a Neuromuscular Blocking Agent

NCT ID: NCT06740877

Last Updated: 2024-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-25

Study Completion Date

2026-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the recent development of image analysis, it has become possible to measure the skeletal muscle index representing the subject's muscle mass from preoperative computed tomography (CT) images. Therefore, in this study, the investigators quantify the skeletal muscle index from preoperative CT images and analyze the correlation with the dose of neuromuscular blocking agent, rocuronium, required for maintaining deep neuromuscular blockade.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Deep neuromuscular blockade improves the condition of surgeon's surgical field during the surgery and reduces the acute postoperative pain. The dosage of neuromuscular blocking agent has been usually administered according to the patient's actual body weight, but even with the same body weight, the ratio of muscle to fat varies from individual to individual, and there are many differences depending on age, gender, and exercise level.

Therefore, if the dose of neuromuscular blocking agent is administered according to actual body weight, additional doses may be required due to insufficient neuromuscular blockade, or excessive doses may occur. However, it was difficult to quantify the muscle mass, with the recent development of image analysis, it has become possible to measure the skeletal muscle index representing the subject's muscle mass from preoperative computed tomography (CT) images. Therefore, in this study, the investigators quantify the skeletal muscle index from preoperative CT images and analyze the correlation with the dose of neuromuscular blocking agent, rocuronium, required for maintaining deep neuromuscular blockade.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Blockade

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Those who voluntarily agreed and signed the written consent form before participating in the study
* American Society of Anesthesiologists physical class (ASA class) 1-3
* Patients scheduled for elective colon surgery under general anesthesia
* Patients undergoing abdominal computed tomography for routine preoperative preparation

Exclusion Criteria

* Pregnant women
* Decreased renal function (GFR\<60mL/min/1.73m2).
* Patients taking drugs that affect deep neuromuscular blockade
* Patients with a history of neuromuscular and muscle disorders
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Bundang Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Park InSun

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Insun Park, M.D./Ph.D.

Role: PRINCIPAL_INVESTIGATOR

assistant professor

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Insun Park, M.D./Ph.D.

Role: CONTACT

Phone: 823178777499

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B-2501-947-303

Identifier Type: -

Identifier Source: org_study_id